Zacks Research Analysts Cut Earnings Estimates for Omnicell

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research cut their FY2027 earnings per share estimates for shares of Omnicell in a research report issued to clients and investors on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.22 per share for the year, down from their previous forecast of $1.36. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

A number of other research firms have also recently issued reports on OMCL. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Wells Fargo & Company reduced their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Barclays raised their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Craig Hallum upped their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Benchmark restated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Omnicell Price Performance

NASDAQ:OMCL opened at $38.47 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.78 billion, a PE ratio of 142.49, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The company’s 50-day moving average price is $42.53 and its two-hundred day moving average price is $43.82.

Insider Buying and Selling at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.64% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pier Capital LLC bought a new stake in shares of Omnicell during the 3rd quarter valued at $5,859,000. Royce & Associates LP bought a new position in shares of Omnicell in the 3rd quarter worth $811,000. Geode Capital Management LLC increased its holdings in Omnicell by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Omnicell by 750.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Omnicell in the third quarter valued at about $753,000. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.